These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 37706450)

  • 21. Structural and Thermodynamic Analysis of HIV-1 Fusion Inhibition Using Small gp41 Mimetic Proteins.
    Jurado S; Cano-Muñoz M; Morel B; Standoli S; Santarossa E; Moog C; Schmidt S; Laumond G; Cámara-Artigas A; Conejero-Lara F
    J Mol Biol; 2019 Aug; 431(17):3091-3106. PubMed ID: 31255705
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adding an Artificial Tail-Anchor to a Peptide-Based HIV-1 Fusion Inhibitor for Improvement of Its Potency and Resistance Profile.
    Su S; Ma Z; Hua C; Li W; Lu L; Jiang S
    Molecules; 2017 Nov; 22(11):. PubMed ID: 29156603
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of a human protein-derived HIV-1 fusion inhibitor targeting the gp41 fusion core structure.
    Chao L; Lu L; Yang H; Zhu Y; Li Y; Wang Q; Yu X; Jiang S; Chen YH
    PLoS One; 2013; 8(5):e66156. PubMed ID: 23741527
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HIV gp41 C-terminal heptad repeat contains multifunctional domains. Relation to mechanisms of action of anti-HIV peptides.
    Liu S; Jing W; Cheung B; Lu H; Sun J; Yan X; Niu J; Farmar J; Wu S; Jiang S
    J Biol Chem; 2007 Mar; 282(13):9612-9620. PubMed ID: 17276993
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Probing Vulnerability of the gp41 C-Terminal Heptad Repeat as Target for Miniprotein HIV Inhibitors.
    Jurado S; Moog C; Cano-Muñoz M; Schmidt S; Laumond G; Ruocco V; Standoli S; Polo-Megías D; Conejero-Lara F; Morel B
    J Mol Biol; 2020 Sep; 432(20):5577-5592. PubMed ID: 32822695
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Different from the HIV fusion inhibitor C34, the anti-HIV drug Fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120.
    Liu S; Lu H; Niu J; Xu Y; Wu S; Jiang S
    J Biol Chem; 2005 Mar; 280(12):11259-73. PubMed ID: 15640162
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Membrane-anchored HIV-1 N-heptad repeat peptides are highly potent cell fusion inhibitors via an altered mode of action.
    Wexler-Cohen Y; Shai Y
    PLoS Pathog; 2009 Jul; 5(7):e1000509. PubMed ID: 19593361
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic Efficacy and Resistance Selection of a Lipopeptide Fusion Inhibitor in Simian Immunodeficiency Virus-Infected Rhesus Macaques.
    Yu D; Xue J; Wei H; Cong Z; Chen T; Zhu Y; Chong H; Wei Q; Qin C; He Y
    J Virol; 2020 Jul; 94(15):. PubMed ID: 32404526
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors.
    Geng X; Liu Z; Yu D; Qin B; Zhu Y; Cui S; Chong H; He Y
    Viruses; 2019 Jul; 11(7):. PubMed ID: 31277353
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sulfono-γ-AApeptides as Helical Mimetics: Crystal Structures and Applications.
    Sang P; Shi Y; Huang B; Xue S; Odom T; Cai J
    Acc Chem Res; 2020 Oct; 53(10):2425-2442. PubMed ID: 32940995
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An amphiphilic conjugate approach toward the design and synthesis of betulinic acid-polyphenol conjugates as inhibitors of the HIV-1 gp41 fusion core formation.
    Liu Y; Ke Z; Wu KY; Liu S; Chen WH; Jiang S; Jiang ZH
    ChemMedChem; 2011 Sep; 6(9):1654-64. PubMed ID: 21688394
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The development of antimicrobial γ-AApeptides.
    She F; Oyesiku O; Zhou P; Zhuang S; Koenig DW; Cai J
    Future Med Chem; 2016 Jun; 8(10):1101-10. PubMed ID: 27284624
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A novel bispecific peptide HIV-1 fusion inhibitor targeting the N-terminal heptad repeat and fusion peptide domains in gp41.
    Jiang X; Jia Q; Lu L; Yu F; Zheng J; Shi W; Cai L; Jiang S; Liu K
    Amino Acids; 2016 Dec; 48(12):2867-2873. PubMed ID: 27631437
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High throughput screening and characterization of HIV-1 entry inhibitors targeting gp41: theories and techniques.
    Liu S; Jiang S
    Curr Pharm Des; 2004; 10(15):1827-43. PubMed ID: 15180543
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multimerized HIV-gp41-derived peptides as fusion inhibitors and vaccines.
    Nomura W; Mizuguchi T; Tamamura H
    Biopolymers; 2016 Nov; 106(4):622-8. PubMed ID: 26583370
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HIV-1 variants with a single-point mutation in the gp41 pocket region exhibiting different susceptibility to HIV fusion inhibitors with pocket- or membrane-binding domain.
    Lu L; Tong P; Yu X; Pan C; Zou P; Chen YH; Jiang S
    Biochim Biophys Acta; 2012 Dec; 1818(12):2950-7. PubMed ID: 22867851
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Conserved residue Lys574 in the cavity of HIV-1 Gp41 coiled-coil domain is critical for six-helix bundle stability and virus entry.
    He Y; Liu S; Jing W; Lu H; Cai D; Chin DJ; Debnath AK; Kirchhoff F; Jiang S
    J Biol Chem; 2007 Aug; 282(35):25631-9. PubMed ID: 17616522
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Lipopeptide HIV-1/2 Fusion Inhibitor with Highly Potent
    Chong H; Xue J; Xiong S; Cong Z; Ding X; Zhu Y; Liu Z; Chen T; Feng Y; He L; Guo Y; Wei Q; Zhou Y; Qin C; He Y
    J Virol; 2017 Jun; 91(11):. PubMed ID: 28356533
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genetic Pathway of HIV-1 Resistance to Novel Fusion Inhibitors Targeting the Gp41 Pocket.
    Su Y; Chong H; Xiong S; Qiao Y; Qiu Z; He Y
    J Virol; 2015 Dec; 89(24):12467-79. PubMed ID: 26446597
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biochemistry and biophysics of HIV-1 gp41 - membrane interactions and implications for HIV-1 envelope protein mediated viral-cell fusion and fusion inhibitor design.
    Cai L; Gochin M; Liu K
    Curr Top Med Chem; 2011 Dec; 11(24):2959-84. PubMed ID: 22044229
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.